Difference between revisions of "Part:BBa K3096016"

(→‎Improvement of Tat (BBa_K1202006) by iGEM Tuebingen 2019)
 
(16 intermediate revisions by 5 users not shown)
Line 1: Line 1:
 
<partinfo>BBa_K3096016 short</partinfo>
 
<partinfo>BBa_K3096016 short</partinfo>
  
−
TAT-LK15 is a short fusion peptide of the cell-penetrating peptide (CPP) Tat (transcactivator of transcription) and the synthetic LK15 peptide. Adding  LK15 to Tat results in improved transport efficiency across the cell membrane. The part has been reported to be able to transport nucleic acids through membranes, which allows for novel transfection protocols (Saleh et al.). LK15 consists of 15 amino acids, which are all either leucine (L) or lysine (K) residue, resulting in an amphipathic protein (Saleh et al.).
+
TAT-LK15 is a short fusion peptide of the cell-penetrating peptide (CPP) TAT (transactivator of transcription) and the synthetic LK15 peptide. Adding  LK15 to TAT results in improved transport efficiency across the cell membrane. The part has been reported to be able to transport nucleic acids through membranes, which allows novel transfection protocols (Saleh et al.). LK15 consists of 15 amino acids, which are all either leucine (L) or lysine (K) residue, resulting in an amphipathic protein (Saleh et al.).
  
 +
===Biology & Usage===
 +
Due to their penetrating activity, '''Cell penetrating peptides''' can be utilized as carriers of small therapeutic macromolecules or nucleic acids across membranes (Kamei et al.). Since cytotoxic effects have occurred, induced by the disintegration of the plasma membrane, improvement and development of cell-penetrating peptides are necessary.
  
−
===Sequence and Features===
+
Kamei et al. propose that cell-penetrating peptides gain their activity through the abundance of multiple positive charges (arginine, R) and the ability to form an amphipathic helix.
−
Tat: RKKRRQRRRGGG-CONH2
+
−
LK15: KLLKLLLKLLLKLLK-COOH
+
−
Tat-LK15: RKKRRQRRRGGGKLLKLLLKLLLKLLK-CONH2
+
  
−
<partinfo>BBa_K3096016 SequenceAndFeatures</partinfo>
+
'''TAT''' is commonly used to deliver DNA across membranes in order to overcome the issues proposed by low transfection efficiency in cell culture (Saleh et al.). It consists of up to 35 amino acids of the HIV-1 full-length protein TAT (Wender et al.). Its penetrating activity is supposed to be induced by guanidinium groups (Wender et al.)
  
−
===Biology & Usage===
+
Saleh et al. showed that TAT's penetrative activity can be significantly increased upon the covalent attachment of '''LK-15''' to TAT. Moreover, they demonstrated that TAT-LK15/DNA complex treatment results in stronger leakage of the membrane, which could be causing the increased transfection activity (Salah et al.).
−
Through their penetrating activity, '''Cell penetrating peptides''' can be utilised as carriers of small therapeutic macromolecules or nucleic acids across membranes (Kamei et al.). Since cytotoxic effects, induced by the disintegration of the plasma membrane, have occured, improvement and development of cell penetrating peptides is necessary.  
+
  
−
Moreover, Kamei et al. propose that cell penetrating peptides gain their activity through the abundance of multiple positive charges (argine, R) and the ability to form an amphipathic helix.
+
===Improvement of TAT (BBa_K1202006) by iGEM Tuebingen 2019===
 +
To improve TAT (BBa_K1202006), iGEM Team Tuebingen has hereby introduced '''TAT-LK15''' to the iGEM registry.
 +
According to Saleh et al., DNA complexes with TAT–LK15 confer to a higher transfection efficiency than TAT. This can be confirmed by our software tool '''C3Pred''' (see below).
  
−
'''Tat''' is commonly used to deliver DNA across membranes in order to overcome the issues proposed by low transfection efficiency in cell culture (Saleh et al.). It consists of up to 35 amino acids of the HIV-1 full length protein Tat (Wender et al.). Its penetrating acitivity is supposed to be induced by guanidinium groups (Wender et al.)
+
===Characterisation of TAT-LK15===
 +
<html>
 +
<p><img src="https://2019.igem.org/wiki/images/b/bb/T--Tuebingen--cpp_table.PNG" alt="Results" style="float:right; width:600px">The improved activity of TAT-LK15 over TAT was confirmed by our CPP transport activity prediction tool <b>C3Pred</b>. TAT-LK15 scored  higher results than the wildtype TAT. This can partly be explained by the presence of multiple positively charged residues in the LK15 peptide, which have been shown to be associated with high transport efficiency by our software tool.</p>
  
−
Saleh et al. have showed that Tat's penetrative activity can be significantly increased upon the covalent attachment of '''LK-15''' to Tat. Moreover, they have demonstrated that Tat-LK15/DNA complex treatment results in stronger leakage of the membrane, which can be a reason for its increased transfection activity (Salah et al.).
 
  
−
===Improvement of Tat (BBa_K1202006) by iGEM Tuebingen 2019===
+
<p>To use the tool and to get more information on how it operates, please visit the wiki of iGEM Team Tübingen 2019.</p>
−
To improve Tat (BBa_K1202006), added to the iGEM registry by iGEM Team, iGEM Team Tuebingen has hereby introduced '''Tat-LK15''' to the iGEM registry.  
+
</html>
−
According to Saleh et al. DNA complexes with Tat–LK15 confer to a higher transfection efficiency than Tat. This can be confirmed by our software tool '''C3Pred''' (see below).
+
  
−
===Characterisation of Tat-LK15===
+
===Biosafety===
−
The improved activity of TAT-LK15 over Tat was confirmed by our CPP transport activity prediction tool '''C3Pred'''. TAT-LK15 scored significantly higher results than the wildtype Tat. This can partly be explained by the presence of multiple positively charged residues in the LK15 peptide, which have been shown to associated with high transport efficiency by our software tool.
+
Together with professional safety officials, Team iGEM Tuebingen 2019 has evaluated the biosafety of cell-penetrating peptides and has come to the conclusion that cell-penetrating peptides are to be classified as BSL1.
  
 +
===Sequence and Features===
 +
Tat: RKKRRQRRRGGG-CONH2
 +
LK15: KLLKLLLKLLLKLLK-COOH
 +
Tat-LK15: RKKRRQRRRGGGKLLKLLLKLLLKLLK-CONH2
  
−
===Biosafety===
+
<partinfo>BBa_K3096016 SequenceAndFeatures</partinfo>
−
Together with professional safety officials, Team iGEM Tuebingen 2019 has evaluated the biosafety of cell penetrating peptides and has come to the conclusion that cell penetrating peptides are to be classified as BSL1.
+
  
 
==References==
 
==References==
 
#'''Saleh, Amer F., et al'''. "Improved Tat-mediated plasmid DNA transfer by fusion to LK15 peptide." ''Journal of Controlled Release'' 143.2 ('''2010'''): 233-242.
 
#'''Saleh, Amer F., et al'''. "Improved Tat-mediated plasmid DNA transfer by fusion to LK15 peptide." ''Journal of Controlled Release'' 143.2 ('''2010'''): 233-242.
 
#'''Kamei, Noriyasu, et al.''' "Usefulness of cell-penetrating peptides to improve intestinal insulin absorption." Journal of Controlled Release 132.1 (2008): 21-25.
 
#'''Kamei, Noriyasu, et al.''' "Usefulness of cell-penetrating peptides to improve intestinal insulin absorption." Journal of Controlled Release 132.1 (2008): 21-25.
−
#'''Paul A. Wender, Dennis J. Mitchell, Kanaka Pattabiraman, Erin T. Pelkey, Lawrence Steinman, Jonathan B. Rothbard''' "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters"
+
#'''Paul A. Wender, Dennis J. Mitchell, Kanaka Pattabiraman, Erin T. Pelkey, Lawrence Steinman, Jonathan B. Rothbard''' "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters". Proceedings of the National Academy of Sciences Nov 2000, 97 (24) 13003-13008; DOI: 10.1073/pnas.97.24.13003
−
Proceedings of the National Academy of Sciences Nov 2000, 97 (24) 13003-13008; DOI: 10.1073/pnas.97.24.13003
+
 
<!-- Uncomment this to enable Functional Parameter display  
 
<!-- Uncomment this to enable Functional Parameter display  
 
===Functional Parameters===
 
===Functional Parameters===
 
<partinfo>BBa_K3096016 parameters</partinfo>
 
<partinfo>BBa_K3096016 parameters</partinfo>
 
<!-- -->
 
<!-- -->

Latest revision as of 07:39, 21 October 2020

Tat-LK15 - improved Cell penetrating peptide

TAT-LK15 is a short fusion peptide of the cell-penetrating peptide (CPP) TAT (transactivator of transcription) and the synthetic LK15 peptide. Adding LK15 to TAT results in improved transport efficiency across the cell membrane. The part has been reported to be able to transport nucleic acids through membranes, which allows novel transfection protocols (Saleh et al.). LK15 consists of 15 amino acids, which are all either leucine (L) or lysine (K) residue, resulting in an amphipathic protein (Saleh et al.).

Biology & Usage

Due to their penetrating activity, Cell penetrating peptides can be utilized as carriers of small therapeutic macromolecules or nucleic acids across membranes (Kamei et al.). Since cytotoxic effects have occurred, induced by the disintegration of the plasma membrane, improvement and development of cell-penetrating peptides are necessary.

Kamei et al. propose that cell-penetrating peptides gain their activity through the abundance of multiple positive charges (arginine, R) and the ability to form an amphipathic helix.

TAT is commonly used to deliver DNA across membranes in order to overcome the issues proposed by low transfection efficiency in cell culture (Saleh et al.). It consists of up to 35 amino acids of the HIV-1 full-length protein TAT (Wender et al.). Its penetrating activity is supposed to be induced by guanidinium groups (Wender et al.)

Saleh et al. showed that TAT's penetrative activity can be significantly increased upon the covalent attachment of LK-15 to TAT. Moreover, they demonstrated that TAT-LK15/DNA complex treatment results in stronger leakage of the membrane, which could be causing the increased transfection activity (Salah et al.).

Improvement of TAT (BBa_K1202006) by iGEM Tuebingen 2019

To improve TAT (BBa_K1202006), iGEM Team Tuebingen has hereby introduced TAT-LK15 to the iGEM registry. According to Saleh et al., DNA complexes with TAT–LK15 confer to a higher transfection efficiency than TAT. This can be confirmed by our software tool C3Pred (see below).

Characterisation of TAT-LK15

ResultsThe improved activity of TAT-LK15 over TAT was confirmed by our CPP transport activity prediction tool C3Pred. TAT-LK15 scored higher results than the wildtype TAT. This can partly be explained by the presence of multiple positively charged residues in the LK15 peptide, which have been shown to be associated with high transport efficiency by our software tool.

To use the tool and to get more information on how it operates, please visit the wiki of iGEM Team Tübingen 2019.

Biosafety

Together with professional safety officials, Team iGEM Tuebingen 2019 has evaluated the biosafety of cell-penetrating peptides and has come to the conclusion that cell-penetrating peptides are to be classified as BSL1.

Sequence and Features

Tat: RKKRRQRRRGGG-CONH2 LK15: KLLKLLLKLLLKLLK-COOH Tat-LK15: RKKRRQRRRGGGKLLKLLLKLLLKLLK-CONH2


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

References

  1. Saleh, Amer F., et al. "Improved Tat-mediated plasmid DNA transfer by fusion to LK15 peptide." Journal of Controlled Release 143.2 (2010): 233-242.
  2. Kamei, Noriyasu, et al. "Usefulness of cell-penetrating peptides to improve intestinal insulin absorption." Journal of Controlled Release 132.1 (2008): 21-25.
  3. Paul A. Wender, Dennis J. Mitchell, Kanaka Pattabiraman, Erin T. Pelkey, Lawrence Steinman, Jonathan B. Rothbard "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters". Proceedings of the National Academy of Sciences Nov 2000, 97 (24) 13003-13008; DOI: 10.1073/pnas.97.24.13003